Hey China! Can China be the next biotech superpower?

Hey China! by Shirley Yu and Martina Fuchs, in partnership with placedelabourse.fr

China has been pumping billions into its R&D ecosystem and clinical infrastructure, and domestic pharma companies are starting to make medical breakthroughs of their own.

But the question remains: can the superpower also become a home for biotech innovators?

Scientific R&D spending topped $291 billion in 2018, just over 2% of GDP, and the government is targeting even higher spending of 2.5% of GDP this year.

The China Pharmaceutical Innovation and Research Development Association estimates that the domestic pharmaceutical sector comprises 4,441 companies. By the end of 2020, 10 to 20 life science parks are planned to be built.

Lots to discuss on Hey China! with Frank Pitzer, Corporate Audit Director for APAC & EMEA at pharma giant Roche, who started off by explaining what it took to build Roche Diagnostics’ factory in Suzhou.

Lots to discuss on Hey China! with Frank Pitzer, Corporate Audit Director for APAC & EMEA at pharma giant Roche, who started off by explaining what it took to build Roche Diagnostics’ factory in Suzhou.

Also in this episode: – Key drivers for innovation in China: “Made in China 2025”, heavy state funding, and favorable regulation

– After a trade and technology war, are we facing a biotech war between the US and China next? – Which are the biotech leaders to watch?

– “You have to be less and less concerned about intellectual property (infringements) in China because they are creating their own IP”

– Why his TED Talk didn’t happen but his message remains: “Youth beats experience”

Hey China! is a digital media production and talk show by Co-Founders and Co-Hosts Shirley Yu and Martina Fuchs and produced by Arwen Zhining Li focusing on China’s tech space.